Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review

Abstract

The IL-17 pathway is a potential therapeutic target shown to be implicated in hidradenitis suppurativa (HS), however, it remains unclear whether evidence from mechanistic studies may translate into clinical practice. This systematic review summarizes available treatment outcomes of IL-17 inhibitors in patients with HS. Embase, MEDLINE, PubMed, and clinicaltrials.gov were comprehensively searched on February 26, 2021 to include 16 original studies representing 128 patients with HS (mean age: 36.5 years; age range: 21-47 years; male: 50.0%). Treatment outcomes were reported for the following biologics: secukinumab (n = 105), brodalumab (n = 22), and ixekizumab (n = 1). Patients were classified as responders or non-responders according to achievement of a positive response/improvement based on criteria established for each included study. For secukinumab 57.1% (n = 60/105) of patients were responders in a mean response period of 16.2 weeks and 42.9% (n = 45/105) were non-responders; for brodalumab, 100.0% (n = 22/22) of patients were responders within 4.4 weeks; and the one patient treated with ixekizumab was a responder within 10 weeks. In conclusion, IL-17 inhibitors may serve as an effective therapeutic target in approximately two-thirds of patients with HS and can be considered in those who are refractory to other treatment modalities. We also stress the importance of consistent outcome measures to enhance evidence synthesis, decrease reporting bias, provide potential for future meta-analysis, and ultimately improve clinical outcomes for patients with HS.

Keywords

Hidradenitis suppurativa IL-17 inhibitors secukinumab brodalumab ixekizumab

Introduction

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic cutaneous disorder characterized by inflammatory nodules, abscesses and fistulae, with lesions most commonly occurring in the groin, inframammary folds and axillae.¹ HS tends to present in the second decade of life, occurs predominantly in females and affects approximately 1% of the population.^1,2 HS has a detrimental impact on physical, social and emotional aspects of life, extending into peoples’ ability to work and complete activities of daily life.^3

-6 A recent study found that HS may have a greater impact on general health when compared to depression, type 2 diabetes, hypertension, congestive heart failure and myocardial infarction.⁷

Therapeutic options for HS have been limited to adalimumab, the only approved biologic for this indication.^1,6 However, recently, as summarized in the expert opinion by Rosales et al. (2020) and systematic review by Frew at el. (2020), an increasing number of promising biologic therapies have been reported to lead to favorable outcomes in HS treatment.^1,6 The IL-17 pathway is a potential therapeutic target shown to be implicated in hidradenitis suppurative (HS) as shown by several experimental studies. For example, Schlapbach et al. (2011) found a 30 fold increase in gene expression of IL-17 and clusters of IL-17 producing T-helper cells in HS lesional tissue as compared to normal skin.⁸ Additionally, Matusiak et al. (2017) found elevated serum levels of IL-17 in HS patients.⁹ However, it remains unclear whether evidence from mechanistic studies may translate into clinical practice.⁶ The objective of this systematic review is to comprehensively summarize treatment outcomes of IL-17 inhibition in patients with HS. This information will be important to physicians managing patients with HS.

Methods

Guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA), were followed for this systematic review.¹⁰

Search Strategy

A literature search utilized Embase, MEDLINE and PubMed databases as well as clinicaltrials.gov on February 26, 2021 using variations of pre-determined keywords, (“hidradenitis suppurativa” or “acne inversa” or “verneuil’s disease” or “pyoderma fistulans significa”) and (“IL 17” or “ixekizumab” or “brodalumab” or “secukinumab”). No date or language restrictions were used.

Eligibility

Articles were included if they reported (i) treatment outcomes of HS patients receiving IL-17 inhibitors, using validated or quantifiable scales, (ii) were observational or experimental studies, with human subjects, and iii) had data in the English language. Examples of non-validated or quantifiable scales which were excluded include “clinical response” and “discharge and nodule counts.”

Data Screening

Title and abstract screening and full text review were completed by two independent researchers (N.K. and A.M.) while conflicts were resolved by discussion with a third reviewer (J.Y.) Relevant articles were manually checked to identify any additional studies.

Quality Appraisal

After full text review, quality appraisal of included studies was assessed independently by two reviewers (N.K. and Y.L.) using the Joanna Briggs Institute (JBI) critical appraisal tools.¹¹ Any conflicts which arose were resolved by discussion between the two reviewers. Guided by the JBI manual for evidence synthesis and based on the number of criteria met for each type of study (Supplemental File 1-4), authors grouped studies into the following categories: (1) good quality, (2) moderate quality, and (3) poor quality. Authors decided to exclude any studies that were of poor quality.¹¹

Data Extraction

Data extraction was completed by two researchers (S.A. and A.R), data verified by another researcher (N.K.) and conflicts resolved by discussion with a third researcher (A.M.) Data were extracted on study and patient characteristics, HS information, biologic information and treatment outcomes.

Definitions

Treatment outcomes of IL-17 inhibitors collected included the following:

Responder: defined as a patient achieving a positive response/improvement based on criteria established for each included study in the review. For example, achieving the Hidradenitis Suppurativa Clinical Response (HiSCR). Table 1 provides a summary of each study’s interpretation of response.

Nonresponder: defined as no response/improvement based on criteria established for each included study in the review. For example, not achieving HiSCR (Table 1).

Mean response period: defined as the mean time between treatment initiation and response/improvement of HS.

Table 1

Summary of Response Measures to Quantify Treatment Outcomes.

Biologic	Author, year	Study design	Sample size	Response measure used	Purpose of response measure	Score before biologic used	Score after biologic used	^aNumber of responders (n)	^bNumber of nonresponders (n)
Secukinumab	Thorlacius et al., 2017	Case Report	1	(1) VAS-Pain (2) HS-PGA	(1) Assesses pain: patient marks on marked line their pain from 0 (no pain) to 10 (worst possible pain) (2) Assesses disease severity takes into account number of abscesses, draining fistulas, inflammatory nodules, noninflammatory nodules. Six stages: clear, minimal, mild, moderate, severe, very severe.	(1) 5 (2) Very severe	(2) 3 (2) Severe	n = 1/1	n = 0/1
	Schuch et al., 2017	Case Report	1	Modified Sartorius Score	Assesses disease severity takes into account the number of inflamed nodules and fistulas, dispersion of lesions and Hurley stage	90	7	n = 1/1	n = 0/1
	Jorgensen et al., 2018	Case Report	1	Modified Sartorius Score	See above	76	19	n = 1/1	n = 0/1
	Prussick et al., 2019	Clinical Trial	9	HiSCR	Assesses disease severity: achieved when there is ≥50% reduction in inflammatory lesion count and no increase in abscesses or draining fistulas when compared with baseline. Additionally, may include at least 50%, 75%, and 100% reductions in AN count (AN50, AN75, and AN100)	NA	Yes (n = 6/9),No (n = 3/9)	n = 6/9	n = 3/9
	Hunger et al., 2019	Clinical Trial	31	HS-PGA	See above	Initial score of at least 3 (n = 31)	Decreased by at least 2 points (n = 10/31)Did not decrease by at least 2 points (n = 21/31)	n = 10/31	n = 21/31
	Glowaczewska et al., 2020	Case Report	1	(1) Modified Sartorius Score(2) HS-PGA(3) VAS-Pain	(1) See above(2) See above(3) See above	(1) 96(2) Severe(3) 7	(1) 17(2) Mild(3) 0	n = 1/1	n = 0/1
	Casseres et al., 2020	Clinical Trial	20	(1) HiSCR(2) Modified sartorius score	(1) See above(2) See above	(1) NA(2) NR	(1) HiSCR: Yes (n = 14/20), AN75 (n = 7/20), and AN100 (n = 3/20); No (n = 6/20)(2) Decreased by mean 51 +/- 77 points (n = 20/20)	n = 14/20	n = 6/20
	Villegas-Romero et al., 2020	Case Report	3	(1) HiSCR(2) Modified sartorius score	(1) See above(2) See above	(1) NA(2) NR	(1) Yes (n = 3/3)(2) Decreased mean of 44 points (n = 3/3)	n = 3/3	n = 0/3
	Chiricozzi et al., 2020	Case Report	1	(1) HiSCR(2) NRS-Pain(3) IHS4	(1) See above(2) Assesses pain: patient rates pain from 0 (no pain) to 10 (worst possible pain)(3) Assesses disease severity: takes into account number of nodules, abscesses, and draining tunnels. Three stages: mild, moderate, severe	(1) NA(2) 7(3) 12	(1) Yes(2) 0(3) 8	n = 1/1	n = 0/1
	Reguiai et al., 2020	Cohort	20	(1) HiSCR(2) HS-PGA	(1) See above(2) See above	(1) NA(2) Mean severe (n = 20/20)	(1) Yes (n = 15/20), No (n = 5/20)(2) Mean mild (n = 20/20)	n = 15/20	n = 5/20
	Ribero et al., 2021	Cohort	17	(1) HiSCR(2) IHS4	(1) See above(2) See above	(1) NA(2) 19	(1) Yes (n = 7/17), AN75 (n = 3/20), and AN100 (n = 2/20); No (n = 10/17)(2) 10	n = 7/17	n = 10/17
Brodalumab	Frew et al., 2020	Cohort	10	HiSCR	See above	NA	HiSCR (n = 10/10),HiSCR-75 (n = 6/10),HiSCR-100 (n = 4/10)	n = 10/10	n = 0/10
Brodalumab	Arenbergerova et al., 2020	Case Report	1	(1) HiSCR(2) VAS-Pain	(1) See above(2) See above	(1) NA(2) 8.7	(1) Yes(2) 5	n = 1/1	n = 0/1
	Frew et al., 2021	Cohort	10	(1) HiSCR(2) IHS4(3) VAS-Pain	(1) See above(2) See above(3) See above	(1) NA(2) NR(3) 6	(1) Yes (n = 10/10), AN75 (n = 8/10), and AN100 (n = 5/10)(2) 1-category change (n = 8/10); 2-category change (n = 5/10)(3) 1.9	n = 10/10	n = 0/10
	Yoshida et al., 2021	Case Report	1	Modified sartorius score	See above	102	30	n = 1/1	n = 0/1
Ixekizumab	Megna et al., 2020	Case Report	1	(1) HiSCR(2) VAS-Pain	(1) See above(2) See above	(1) NA(2) 4	(1) Yes(2) 1	n = 1/1	n = 0/1

Abbreviations: AN: inflammatory nodules; CR: complete resolution; HiSCR: Hidradenitis Suppurativa Clinical Response; HSS: Hidradenitis Suppurativa Score; IHS4: International Hidradenitis Suppurativa Severity Score System; NA: not applicable; NR: not reported, PR: partial resolution; PGA: physician global assessment; VAS: visual analog scale.

^aResponder: a patient achieving a positive response/improvement based on criteria established for each included study.

^bNon-responder: a patient achieving no response/improvement based on criteria established for each included study.

Level of Evidence

The Oxford Centre for Evidence-Based Medicine 2011 Levels of Evidence were used to determine level of evidence for included articles.¹² Due to the heterogeneity of data, only descriptive analysis was performed, no meta-analysis was completed.

Results

Study and Patient Characteristics

Of the 311 studies identified, 36 full texts were assessed for eligibility and 16 met inclusion criteria, representing 128 patients (mean age: 36.5 years; age range: 21-47 years; male: 50.0%) (Supplemental File 5-6).^{13

-28} Studies included 9 case reports, 4 cohort studies and 3 clinical trials. Level of evidence analysis yielded 9 studies with a level of evidence of 5, 4 studies with level of evidence of 2, and 3 studies with level of evidence of 1. Treatments outcomes were reported for the following biologics: secukinumab (n = 105), brodalumab (n = 22) and ixekizumab (n = 1).

Outcome Measures

Table 1 summarizes the outcome measures reported in included studies to quantify treatment outcomes. In total, 17 different outcome measures were used to mark treatment outcomes of HS in patients on IL-17 inhibitors (mean per study: 4; median per study: 4; range: 1 to 9). Most commonly, HiSCR and the Dermatology Life Quality Index were reported in 68.8% (n = 11/16) studies each, the Modified Sartorius Score (MSS) in 56.3% (n = 9/16) studies each, and the International Hidradenitis Suppurativa Severity Score System (IHS4) in 50.0% (n = 8/16) studies (Supplemental File 7). Next, the pain Visual Analog Scale (VAS) was reported in 37.5% (n = 6/16) studies, the HS-Physician Global Assessment (HS-PGA) in 25.5% (n = 4/16) studies and the Global Disease Assessment VAS was reported in 13.3% (n = 3/16) studies. Further, the pain/utility/handicap VAS and three other outcome measures were reported in 12.5% (n = 2/16) studies each, and finally the Hidradenitis Suppurativa Severity Index (HSSI) and five other outcome measures were reported in 6.3% (n = 1/15) studies each.

Secukinumab

In 105 patients who received secukinumab, available data showed that 56.3% (n = 27/48) of patients were Hurley Stage 3, 37.5% (n = 18/48) Hurley Stage 2, 4.2% (n = 2/48) Hurley Stage 1, and 2.1% (n = 1/48) Refined Hurley Stage 2C. Overall, 57.1% (n = 60/105) of patients were responders in a mean response period of 16.2 weeks (Supplemental File 8) and 42.9% (n = 45/105) were non-responders. Overall, 69 adverse events occurred in 34.3% (n = 36/105) of patients. Most commonly, adverse events included gastrointestinal upset (n = 13), self-resolving upper respiratory tract infections (n = 8), nasopharyngitis (n = 7), cutaneous effects (n = 6), back pain (n = 5) and headaches (n = 4). Concomitant medications were reported in only 2.9% (n = 3/105) of patients. These included intralesional triamcinolone; dapsone; or hydroxychloroquine, oral steroids, acetylsalicylic acid and pregabalin in 33.3% (n = 1/3 each).

Brodalumab

Of the 22 patients who received brodalumab, available data showed that 25.0% (n = 3/12) were Hurley Stage 3% and 75.0% (n = 9/12) Hurley Stage 2. Overall, 100.0% (n = 22/22) of patients were responders in a mean response period of 4.4 weeks. Overall, one patient (4.5%) experienced upper respiratory tract infection after receiving brodalumab. Additionally, concomitant medications were reported in 0.0% (n = 0/22) of patients.

Ixekizumab

Finally, one patient with Hurley Stage 2 disease was treated with ixekizumab, was classified as a responder in 10 weeks of treatment without adverse events. No concomitant medications were reported.

Discussion

This systematic review comprehensively summarizes treatment outcomes of IL-17 inhibitors in patients with HS. In total, 16 studies, representing 128 patients, were included. Approximately two-thirds of patients with HS treated with IL-17 inhibitors were classified as responders (64.8%, n = 83/128), suggesting that the IL-17 mechanistic pathway is an effective therapeutic target in HS. Additionally, findings highlight the heterogeneity of HS outcome measures in the literature.

While the exact pathogenesis of HS is unknown, the IL-17 pathway has been demonstrated to play a role in the associated immunopathological process.¹ In normal functioning skin, IL-17 is important for barrier function by inducing inflammatory cytokines, chemokines, antimicrobial peptides and metalloproteinases.²⁹ However, dysregulation promotes inflammatory processes by which IL-17 activates keratinocytes promoting a feedforward loop.³⁰ In HS patients, elevated levels of IL-17A/C/F transcripts in lesional tissue, IL-17A in serum, and CD4+ IL-17 + T cells in lesional and perilesional tissue have all been reported.^{6,8,9,31

-35} Additionally, Th17 cells, characterised by production of IL-17,³⁶ have been found to be rich within HS lesional tissue,⁸ and mesenchymal stem cells to secrete increased levels of IL-17A.³⁷ IL-17A and IL-17F work synergistically with other cytokines to increase inflammatory cytokine and chemokines.³⁸ IL-17C, upon stimulation by IL17A and IL-17F elevates the production of inflammatory cytokines, including IL-17A and IL-17F by Th17 cells, creating an inflammatory feedback loop.^30,39,40 Further, IL-17 induces the proteins LL37/cathelicidin, S100A7, S100A8, and S100A9 which are involved in cytokine and chemokine expression and keratinocyte proliferation, also found in HS patient lesional tissue and serum.^41
-43 Interestingly, IL-17 overexpression has not only been found in lesional and perilesional tissue in HS patients, but also in unaffected skin, suggesting subclinical inflammatory processes occur prior to development of active lesional tissue.⁴¹

IL-17 inflammatory effects can be inhibited by therapeutic binding to IL-17RA, IL-17A, or IL-17F.³⁰ Specifically, secukinumab and ixekizumab have been shown to bind to IL-17A, inhibiting part of the cytokine and inflammatory cascade,¹³ however, still allowing IL-17F to signal the receptor.³⁰ Our results support these mechanistic pathways with 57.5% (n = 61/106) of patients classified as responders. Brodalumab binds to the IL-17RA, blocking a wider range of IL-17 isoforms including IL-17A, IL-17C, and IL-17F.^26,30 One hundred percent (n = 22/22) of patients were responders to brodalumab in our analysis, supporting its wider range of involvement in the IL-17 pathway. With 64.8% (n = 83/128) of patients responding to IL-17 therapies, the clinical response observed in our review further substantiates the role of IL-17 in HS pathogenesis and the need to explore this target. Clinical trials assessing the role of IL-1, IL-17, IL-23, IL-12/23, IL-36, and complement C5a blockade, along with JAK inhibitors, are under way and their results are likely to provide greater insight into both clinical and mechanistic aspects of HS.³⁰

Heterogeneity of reported outcome measures must be discussed, as comparing treatment outcomes requires consistent and valid outcome measures.⁴⁴ The current gold standard outcome measure for assessment of therapeutic options for HS is the HiSCR,⁴⁴ defined as a reduction in inflammatory lesion count (≥50%), which includes abscesses and inflammatory nodules, and no increase in abscesses or draining fistulas.⁴⁵ The HiSCR has been validated for assessment of treatment efficacy,⁴⁵ however, the HiSCR does not take into account draining fistulae in advanced disease, may account for high placebo response rates in evaluating therapeutic options, has poor inter-rater reliability, and may be effected by patient characteristics including Body Mass Index , smoking status, antibiotic use, and draining tunnels.^44
-46

After the introduction of the HiSCR, several other outcome measures such as the HS-PGA and the IHS4 have been developed. In fact, there are 30 or more outcome measures for HS,⁴⁷ however, their validation is incomplete or of low quality;⁴⁸ data regarding comparison of outcome measures within a common cohort is lacking;⁴⁴ and many lack data regarding minimal clinically important differences,⁴⁹ leading to variation in their use. One study which assessed inter-rater reliability of HS outcome measures found that the HS-PGA had moderate inter-rater reliability and the IHS4 had fair inter-rater reliability.⁴⁸ For the MSS and HSSI, intervals for limits of agreement were very wide relative to scale ranges.⁴⁸ Heterogeneity of outcome measures provides the potential for selective reporting leading to outcome reporting bias,⁴⁷ limits evidence synthesis and potentially impacts the quality of our results.

Additionally, disease processes in Hurley Stage 2 versus Stage 3 disease must be considered. Different treatment outcomes between Hurley Stage 2 and 3 have been reported for adalimumab, highlighting the potential for pathogenic heterogeneity between stages to be implicated in variable responses to therapeutics.^46,50,51 It is suggested that this may be due to TNF-α being the dominant therapeutic target in Hurley Stage 1 and 2, with Th17 pathways emerging with increasing severity of disease.⁵² However, current data suggesting different response between stages presents sample sizes too small for statistical significance.⁴⁶ Unfortunately, data is lacking in included studies on how many patients of each Hurley Stage were responders. Thus, our results are unable to provide insight into the potential for pathogenic heterogeneity between stages to be implicated in variable responses to IL-17 inhibitors. We encourage future studies to report how many patients of each stage are responders.

As discussed above, a major limitation of this review includes heterogeneity of included outcome measures, potentially leading to outcome reporting bias, limiting evidence synthesis, and impacting the quality of our results. Additional limitations of this review include small samples sizes, which may limit the generalizability of our findings; and publication bias, with positive findings being more frequently published, potentially inflating the improvement shown in our results.

Despite these limitations, this review provides important clinical conclusions. First, IL-17 inhibitors may serve as an effective therapeutic target in approximately two-thirds of patients with HS and could be considered in those who are refractory to other treatment modalities. Additionally, as only 2.3% (n = 3/128) of patients received concomitant treatment, we believe reported outcomes can be attributed to IL-17 inhibition. Our findings also stress the importance of consistent outcome measures to enhance evidence synthesis, decrease reporting bias, provide potential for future meta-analysis, and ultimately provide patients with the most effective treatments. Further large-scale trials are needed to confirm our findings.

Supplemental Material

Online supplementary file 1 - Supplemental material for Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review

Supplemental material, Online supplementary file 1, for Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review by Nadia Kashetsky, Asfandyar Mufti, Shaikhah Alabdulrazzaq, Yuliya Lytvyn, Muskaan Sachdeva, Abdullah Rahat and Jensen Yeung in Journal of Cutaneous Medicine and Surgery

Footnotes

Declaration of Conflicting Interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Jensen Yeung has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GSK, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, Valeant, and Xenon. Ms. Kashetsky, Dr. Mufti, Dr. Alabdulrazzaq, Mrs. Lytvyn, Ms. Sachdeva, and Mr. Rahat have nothing to declare.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Nadia Kashetsky

Asfandyar Mufti

Yuliya Lytvyn

Muskaan Sachdeva

Supplemental Material

Supplemental material for this article is available online.

References

Rosales Santillan

Morss

PC.

Porter

ML.

Kimball

. Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther. 2020;20(6):621-633.doi:10.1080/14712598.2020.1732918

32077334

Ingram

JR.

Jenkins-Jones

Knipe

DW.

Morgan

CLI.

Cannings-John

Piguet

. Population-based clinical practice research datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178(4):917-924.doi:10.1111/bjd.16101

29094346

Gooderham

Papp

. The psychosocial impact of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S19-S22.doi:10.1016/j.jaad.2015.07.054

26470609

Esmann

Jemec

GBE

. Psychosocial impact of hidradenitis suppurativa: a qualitative study. Acta Derm Venereol. 2011;91(3):328-332.doi:10.2340/00015555-1082

21394419

Hamzavi

IH.

Sundaram

Nicholson

et al. Uncovering burden disparity: a comparative analysis of the impact of moderate-to-severe psoriasis and hidradenitis suppurativa. J Am Acad Dermatol. 2017;77(6):1038-1046.doi:10.1016/j.jaad.2017.07.027

28917381

Frew

JW.

Marzano

AV.

Wolk

et al. A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance. J Invest Dermatol. 2021;141(2):316-324.doi:10.1016/j.jid.2020.06.019

32919760

Sampogna

Fania

Mazzanti

et al. The impact of hidradenitis suppurativa on general health is higher than that of hypertension, congestive heart failure, type 2 diabetes, myocardial infarction and depression. J Eur Acad Dermatol Venereol. 2020;34(8):e386-e388.doi:10.1111/jdv.16290

32043666

Schlapbach

Hänni

Yawalkar

Hunger

. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790-798.doi:10.1016/j.jaad.2010.07.010

21641076

Matusiak

Ł.

Szczęch

Bieniek

Nowicka-Suszko

Szepietowski

. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. 2017;76(4):670-675.doi:10.1016/j.jaad.2016.10.042

28041632

10.

Moher

Liberati

Tetzlaff

Altman

et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097

11.

Moola

Munn

Tufanaru

. Chapter 7: Systematic Reviews of Etiology and Risk. In: JBI Manual for Evidence Synthesis. JBI; 2020.doi:10.46658/jbimes-20-08

12.

Phillips

Ball

Sackett

Badenoch

Straus

Brian Haynes

. Oxford centre for evidence-based medicine - Levels of evidence (March 2009) - CEBM. Nowember. 1998.doi:10.1073/pnas.082117599

13.

Thorlacius

Theut Riis

Jemec

GBE

. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. 2018;179(1):182-185.doi:10.1111/bjd.15769

28654150

14.

Schuch

Fischer

Boehner

Biedermann

Volz

. Successful treatment of severe recalcitrant hidradenitis suppurativa with the interleukin-17A antibody secukinumab. Acta Derm Venereol. 2018;98(1):151-152.doi:10.2340/00015555-2794

28902952

15.

Jørgensen

A-HR.

Yao

Thomsen

. Therapeutic response to Secukinumab in a 36-year-old woman with hidradenitis suppurativa. Case Rep Dermatol Med. 2016;2018(2018):1-3.doi:10.1155/2018/8685136

16.

Megna

Ruggiero

Di Guida

Patrì

Fabbrocini

Marasca

. Ixekizumab: an efficacious treatment for both psoriasis and hidradenitis suppurativa. Dermatol Ther. 2020;33(4):e13756. doi:10.1111/dth.13756

32495491

17.

Yoshida

Oyama

lino

Chimizu

Hasegawa

. Long‐standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: a possible involvement of Th17 across the spectrum of both diseases. J Dermatol. 2021:1-9.doi:10.1111/1346-8138.15807

18.

Frew

JW.

Navrazhina

Sullivan-Whalen

Gilleaudeau

Garcet

Krueger

. Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study. Br J Dermatol. 2021;184(2):350-352.doi:10.1111/bjd.19478

32974912

19.

Ribero

Ramondetta

Fabbrocini

et al. Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. 2021;35(7):e441-e442.doi:10.1111/jdv.17178

33594790

20.

Hunger

French

Prens

et al. Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients - Full Text View - ClinicalTrials.gov. clinicaltrials.gov. Accessed February 28, 2021. https://clinicaltrials.gov/ct2/show/study/NCT02421172?id=NCT03099980+OR+NCT02421172+OR+NCT03960268&draw=2&rank=3&load=cart. Published 2019

21.

Prussick

Rothstein

Joshipura

et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. 2019;181(3):609-611.doi:10.1111/bjd.17822

30801662

22.

Casseres

RG.

Prussick

Zancanaro

et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol. 2020;82(6):1524-1526.doi:10.1016/j.jaad.2020.02.005

32044410

23.

Villegas-Romero

Collantes-Rodríguez

Valenzuela-Ubiña

Jiménez-Gallo

. Moderate to severe hidradenitis suppurativa successfully treated with Secukinumab. Actas Dermosifiliogr. 2020;111(8):3-5.doi:10.1016/j.ad.2019.07.007

32553985

24.

Głowaczewska

Szepietowski

JC.

Matusiak

. Severe hidradenitis suppurativa successfully treated with secukinumab. Dermatol Ther. 2020;33(6):e13845. doi:10.1111/dth.13845

32544258

25.

Reguiaï

Fougerousse

AC.

Maccari

Bécherel

. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). J Eur Acad Dermatol Venereol. 2020;34(11):2-6.doi:10.1111/jdv.16605

32401354

26.

Frew

JW.

Navrazhina

Grand

et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020.doi:10.1016/j.jaad.2020.05.007

27.

Chiricozzi

Garcovich

Malvaso

Giovanardi

Peris

. COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus dear. Int Soc Dermatology. 2020.

28.

Arenbergerova

Arenberger

Marques

Gkalpakiotis

. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure. Int J Dermatol. 2020;59(6):733-735.doi:10.1111/ijd.14792

32012238

29.

McGeachy

MJ.

Cua

DJ.

Gaffen

. The IL-17 family of cytokines in health and disease. Immunity. 2019;50(4):892-906.doi:10.1016/j.immuni.2019.03.021

30995505

30.

Fletcher

JM.

Moran

Petrasca

Smith

. Il-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clin Exp Immunol. 2020;201(2):121-134.doi:10.1111/cei.13449

32379344

31.

Moran

Sweeney

CM.

Hughes

et al. Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which Is corrected by anti-TNF therapy. J Invest Dermatol. 2017;137(11):2389-2395.doi:10.1016/j.jid.2017.05.033

28652108

32.

Wolk

Warszawska

Hoeflich

et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J Immunol. 2011;186(2):1228-1239.doi:10.4049/jimmunol.0903907

21148041

33.

Navrazhina

Frew

JW.

Krueger

. Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa. Br J Dermatol. 2020;182(4):1045-1047.doi:10.1111/bjd.18556

31556100

34.

Witte-Händel

Wolk

Tsaousi

et al. The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol. 2019;139(6):1294-1305.doi:10.1016/j.jid.2018.11.018

30528824

35.

Jiménez-Gallo

de la Varga-Martínez

Ossorio-García

Collantes-Rodríguez

Rodríguez

Linares-Barrios

. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa. Cytokine. 2018;103:20-24.doi:10.1016/j.cyto.2017.12.020

29289722

36.

Tesmer

LA.

Lundy

SK.

Sarkar

Fox

. Th17 cells in human disease. Immunol Rev. 2008;223(1):87-113.doi:10.1111/j.1600-065X.2008.00628.x

18613831

37.

Campanati

Orciani

Sorgentoni

Consales

Offidani

Di Primio

. Pathogenetic characteristics of mesenchymal stem cells in hidradenitis suppurativa. JAMA Dermatol. 2018;154(10):1184-1190.doi:10.1001/jamadermatol.2018.2516

30140888

38.

Frew

JW.

Hawkes

JE.

Krueger

. A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa [version 1; referees: 2 approved, 1 approved with reservations]. F1000Research. 1930;2018:7.doi:10.12688/f1000research.17267.1

39.

Ramirez-Carrozzi

Sambandam

Luis

et al. Il-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12(12):1159-1166.doi:10.1038/ni.2156

21993848

40.

Guttman-Yassky

Krueger

. IL-17C: A unique epithelial cytokine with potential for targeting across the spectrum of atopic dermatitis and psoriasis. J Invest Dermatol. 2018;138(7):1467-1469.doi:10.1016/j.jid.2018.02.037

29941097

41.

Del Duca

Morelli

Bennardo

Di Raimondo

Nisticò

. Cytokine pathways and investigational target therapies in hidradenitis suppurativa. Int J Mol Sci. 2020;21(22):1-23.doi:10.3390/ijms21228436

33182701

42.

Lima

AL.

Karl

Giner

et al. Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa. Br J Dermatol. 2016;174(3):514-521.doi:10.1111/bjd.14214

26436522

43.

Hotz

Boniotto

Guguin

et al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J Invest Dermatol. 2016;136(9):1768-1780.doi:10.1016/j.jid.2016.04.036

27206704

44.

Frew

JW.

Jiang

CS.

Singh

et al. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of pioneer 1 and 2 individual patient data. J Am Acad Dermatol. 2020;82(5):1150-1157.doi:10.1016/j.jaad.2019.12.044

31881294

45.

Kimball

AB.

Jemec

GBE.

Yang

et al. Assessing the validity, responsiveness and meaningfulness of the hidradenitis suppurativa clinical response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434-1442.doi:10.1111/bjd.13270

25040429

46.

Frew

JW.

Editor

. Assessing the efficacy of new biologic therapies in hidradenitis suppurativa: consistency vs. bias in outcome measures in moderate and severe disease. J Eur Acad Dermatol Venereol. 2019;33(8):e298-e300.doi:10.1111/jdv.15572

30875132

47.

Thorlacius

Ingram

JR.

Villumsen

et al. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol. 2018;179(3):642-650.doi:10.1111/bjd.16672

48.

Thorlacius

Garg

Riis

et al. Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa. Br J Dermatol. 2019;181(3):483-491.doi:10.1111/bjd.17716

30724351

49.

Ingram

JR.

Hadjieconomou

Piguet

. Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process. Br J Dermatol. 2016;175(2):263-272.doi:10.1111/bjd.14475

26873867

50.

Kimball

AB.

Okun

MM.

Williams

et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422-434.doi:10.1056/NEJMoa1504370

27518661

51.

Theut Riis

Saunte

DM.

Benhadou

et al. Low and high body mass index in hidradenitis suppurativa patients-different subtypes? J Eur Acad Dermatol Venereol. 2018;32(2):307-312.doi:10.1111/jdv.14599

52.

Frew

. Analysis of Outcome Measures in Hidradenitis Suppurativa. Vivli - Center for Global Clinical Research Data. Published 2020. Accessed December 27, 2020. https://vivli.org/analysis-of-outcome-measures-in-hidradenitis-suppurativa/

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.31 MB